Be sure to visit Agendia’s booth at SABCS 2020

Agendia will present new data from ongoing clinical research evaluating the MammaPrint® and BluePrint® genomic tests at the upcoming 2020 San Antonio Breast Cancer Symposium

These data, which build upon existing clinical research that demonstrates the efficacy of MammaPrint and BluePrint testing to consistently inform optimal treatment planning, highlight Agendia’s many trials in progress that will ultimately impact patient treatment and outcomes.

Agendia’s key activities at SABCS:

Product theater with Q&A featuring MINDACT and NBRST updates

  • Title: Integrating MammaPrint and BluePrint into Pre- and Post-Operative Patient Care
  • Date: Wednesday, December 9 at 10:00 am CST
  • Speaker: William Audeh, MD, Pat Whitworth, MD, David Hicks, MD

Data highlights:

  • Title: BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial
    • Authors: Krop, I., et al.
    • Session: Spotlight Poster Discussion 3 | Wednesday, December 9, 2020 | 6:30pm – 7:30pm CST
    • Poster #: PD3-01
  • Title: 5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival
    • Authors: Whitworth, P., et al.
    • Session: Spotlight Poster Discussion 9 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
    • Poster #: PD9-01

#IAMHERE:

Virtual booth:

  • Visit our virtual booth for more information and to speak with a member of our team
Click Here To Register Today

Following are details of additional Agendia abstracts that have been
accepted for SABCS 2020:

How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status

  • Authors: van’t Veer, L.J., et al.
  • Session: General Session 4 | Friday, December 11, 2020 | 8:45am – 11:30am CST
  • Poster #: PS6-01
  • Presentation #: Oral Presentation GS4-11 | Presentation 11:15am-11:25am CST | Live Q&A Session 11:25am-11:30am CST
View Presentation Here

Molecular subtyping by BluePrint improves prediction of treatment responses and survival outcomes in patients with discordant clinical and genomic classification

  • Authors: Whitworth, P., et al.
  • Session: Poster Session 4
  • Poster #: PS4-04
View Poster Here


5-year outcomes in the NBRST trial: Preoperative MammaPrint and BluePrint breast cancer subtype is associated with neoadjuvant treatment response and survival

  • Authors: Whitworth, P., et al.
  • Session: Spotlight Poster Discussion 9 | Thursday, December 10, 2020 | 3:30pm – 4:45pm CST
  • Poster #: PD9-01
View Poster Here

Racial disparities within Basal-type breast cancer: clinical and molecular features of African American and Caucasian obese patients

  • Authors: Sharma, D., et al.
  • Session: Poster Session 7
  • Poster #: PS7-68
View Poster Here

Molecular profiles and clinical-pathological features of Asian early-stage breast cancer patients

  • Authors: Chen, M., et al.
  • Session: Poster Session 7
  • Poster #: PS7-69
View Poster Here

Differential gene expression analysis and clinical utility of MammaPrint and BluePrint in male breast cancer patients

  • Authors: Crozier, J., et al.
  • Session: Poster Session 14
  • Poster #: PS14-11
View Poster Here

Differential gene expression in Luminal-type invasive lobular carcinoma and invasive ductal carcinoma by MammaPrint risk stratification

  • Authors: Lesnikoski, B., et al.
  • Session: Poster Session 18
  • Poster #: PS18-03
View Poster Here

Using BluePrint to elucidate the molecular heterogeneity of triple negative breast cancers

  • Authors: Kaklamani, V.G., et al.
  • Session: Poster Session 18
  • Poster #: PS18-05
View Poster Here

BluePrint performance in predicting pertuzumab benefit in genomically HER2-positive patients: a biomarker analysis of the APHINITY trial

  • Authors: Krop, I., et al.
  • Session: Spotlight Poster Discussion 3 | Wednesday, December 9, 2020 | 6:30pm – 7:30pm CST
  • Poster #: PD3-01
View Poster Here

Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens

  • Authors: McKelley, J., et al.
  • Session: Poster Session 6
  • Poster #: PS6-19
View Poster Here

The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in patients aged ≥70 years from the population-based observational FOCUS cohort.

  • Authors: Noordhoek, I., et al.
  • Session: Poster Session 6
  • Poster #: PS6-06
View Poster Here

The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer

  • Authors: Lee, L., et al.
  • Session: Ongoing Trials Posters
  • Poster #: OT-12-01
View Poster Here

MammaPrint and BluePrint as prognostic indicators for elderly patients with early stage breast cancer

  • Authors: Blumencranz, P.W., et al.
  • Session: Poster Session 6
  • Poster #: PS6-41
View Poster Here

These data underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.

Please follow us on our TwitterFacebook and LinkedIn pages for unique content we will be sharing throughout SABCS.

Contact Us Today!

For more information on how to order MammaPrint + BluePrint for your patients, please complete the below contact form or call Customer Care at 1-888-321-2732